Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.

WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck to Participate in Cowen's 42nd Annual Health Care Conference

Merck to Participate in Cowen's 42nd Annual Health Care Conference

Bank of America

Intelsat

Blue-chips are particularly attractive at the moment given all of the different question marks investors have to ponder about the economy going forward.

3 Blue Chip Bargain Stocks to Buy Now

GlaxoSmithKline

Vir Biotechnology

Walgreens

CVS Health

Kroger

Rite Aid

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediately after. The cost will be funded by the federal government, which could result in a huge boost to the revenue of companies in the pharmaceutical, pharmacy and diagnostic industries over the coming year.

Health Care Stocks to Watch as Test to Treat Plan Looks to Prevent Lockdowns

Moderna

Pfizer

Thermo Fisher Scientific

President Joe Biden announced during his State of the Union address on Tuesday that individuals who test positive for Covid-19 at a pharmacy will soon be able to get free antiviral treatments immediately after. The cost will be funded by the federal government, which could result in a huge boost to the revenue of companies in the pharmaceutical, pharmacy, and diagnostic industries over the coming year.

Test to Treat Plan can Boost these Stocks

MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belén Garijo on Q4 2021 Results - Earnings Call Transcript

Regeneron Pharmaceuticals

The WHO panel is also evaluating data for Pfizer's antiviral pill, paxlovid, and a widely available antidepressant, fluvoxamine, to treat Covid-19.

WHO Backs Merck's Antiviral Pill For High-Risk Covid Patients But Finds Regeneron's Antibody Cocktail ‘Ineffective' Against Omicron

The stock price of Merck (NYSE: MRK) has seen a fall of 6% over the last month, while it is down 1% year-to-date.

What's Next For Merck Stock After A 6% Fall In A Month?

Germany's Merck KGaA said it expected strong earnings growth this year, driven by its Life Science unit, which supplies materials and gear to COVID-19 vaccine makers and to a buoyant pharmaceuticals industry.

Merck KGaA predicts more earnings gains on lab supplies demand

Amgen

Boeing

Caterpillar

Salesforce

Chevron

Disney

Goldman Sachs

Intel

JPMorgan Chase & Co

Coca-Cola

Microsoft

NIKE

Visa

Verizon

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration."

Dogs Of The Dow For March Drop Closer To Buy Points

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Dr. Julie L. Gerberding to Retire from Merck

Dr. Julie L. Gerberding to Retire from Merck

Adobe

British American Tobacco

Comcast

Cummins

Carlisle Companies

Enbridge

Enterprise Products Partners

Federal Realty Investment Trust

Lincoln Electric Hlds

Lowe's

Magellan Midstream Partners

Altria

Medical Properties Trust

Realty Income Corp

Philip Morris

PPG Industries

Target

V.F.

When the invasion we'd been expecting for weeks finally happened, smart investors were ready to take advantage of short-term market terror. I personally used the Dividend Kings correction planning tool to put $90,000 to work in dozens of the world's best blue-chip

My Oh My, Potential 25 Retirement Blue-Chip Buys

Cisco Systems

Home Depot

Procter & Gamble

Exxon Mobil

Remove the worry associated with volatile, unpredictable stock markets by buying these dividend-paying safe stocks. The post 7 Safe Defensive Stocks to Buy as Market Agitation Rises appeared first on InvestorPlace.

7 Safe Defensive Stocks to Buy as Market Agitation Rises

Stryker

UnitedHealth Group

Each of these stocks dominates their industry within the healthcare sector.

3 Healthcare Stocks That Could Set You Up for Life

KENILWORTH, N.J. & TOKYO--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma

Organon & Co

Shares of Organon & Co. ( OGN , Financial) are up nearly 7% since the pharma company was spun off by Merck & Co. Inc. ( MRK , Financial) in the middle of 2021. And even bluer skies appear to be on the horizon as the company prepares to launch its version of the best-selling medication ever.

Organon Shares Up About 7% Since Merck Spinoff

Bank of Nova Scotia

Novartis

Russia's invasion of Ukraine has combined with rising interest rates and high market valuations to spark the 2022 correction.

The World's 10 Best Rich Retirement Blue-Chips You Can Safely Buy Today

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck Shares Environmental, Social & Governance Priorities and Strategy

Merck Shares Environmental, Social & Governance Priorities and Strategy

Eli Lilly

Yes, but it isn't a worst-case scenario by any means.

Is Inflation a Threat for Pharma Stocks?

After disappointing trial results led to canceled orders, an encouraging new study may give Merck's anti-Covid pill a new boost.

Merck's Anti-Covid Pill Shows Better Effectiveness In Indian Study

Acadia Healthcare

Two vastly different stocks with one common theme: value with growth.

2 Top Healthcare Stocks Ready for a Bull Run

News for Merck Stock (MRK)